Another AGM Q and A2 Apr 2023 11:40
Again, word for word, and a very pertinent and enduring question for many of us - (The shareholder's first name was given by LD but it is not relevant here I don't think)
‘Why do you believe the stock market doesn’t believe the good news of our story, and is it that we don’t have strong enough PR into that area of the advertising stock market?'
Lindy - 'We do not have an approved cancer vaccine, so there is a lot of cynicism out there that cancer vaccines can actually work, so for instance the deal we’ve done with the antibodies wasn’t even for a product, it was for a target and it was a great deal because there’s lots of antibodies already approved, so people know what they’re looking for, they know how they’re going to work, they feel confident, and comfortable with that whole area. There are still a lot of scepticisms about the vaccine. So therefore we need to go further, and that we already know. We’re in the clinic now, good news. We’re recruiting, good news. We’re getting T cell responses – good news. But we need clinical responses as well. First patient’s looking good but we need more than one patient to convince people. It will be the flip side – if this really is working and looking good there will be huge enthusiasm. We’ve had to go longer and deeper, but when we get there it will be a bigger story because we will have achieved what nobody else has achieved and like everything when you’re the first it’s tougher. At that point maybe we need different or better or stronger PR and I think there’s lots of people – Simon and his team amongst them waiting for that moment to go out and shout about it, it’s just that little bit too soon. But soon - we’re getting there definitely, that’s the exciting bit.'
(Note - WHEN we get there it WILL l be a bigger story because we WILL have achieved what nobody else has achieved)
And finally, a comment which has been posted before but bears repeating, from Martin Diggle - (in his words wearing his shareholder’s hat as opposed to his board hat) ‘It’s fair to say we’ve been invested in over a dozen life science companies in the last decade, and this is probably the most exciting thing we’ve ever seen, so well done.’
Sign In
Follow the stocks
